JY016 for EGFR-positive advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called JY016 for people with solid tumors that have the EGFR protein. It is for patients whose cancer has not responded to other treatments. The goal is to see if JY016 can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer has tested positive for the EGFR protein (IHC 1+, 2+, or 3+).
- You have tried standard treatments and they no longer work, or you cannot take them.
- You are in generally good health (able to take care of yourself, daily activities are not limited).
- You have not had certain prior cancer treatments (like CD3-targeted drugs or CAR-T therapy).
- Your cancer has not spread to the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called JH021 in people with advanced cancer that has stopped responding to standard treatments. The drug may help patients with certain lung cancers (NSCLC with specific EGFR mutations) or other solid tumors grow back after other therapies have failed.
This trial tests a new drug, YH32364, for people with advanced solid tumors that have high levels of EGFR protein. It looks at whether the drug can help when standard treatments have stopped working.
This early-phase trial tests a new drug (ZZ06) in adults with advanced solid cancers that have an EGFR “positive” tumor test result. It’s for people whose cancer has grown despite standard treatment or who don’t have a standard option.
This trial tests a new drug called JYP0035 alone in people with advanced solid tumors. It aims to see if the drug is safe and effective.
This trial tests a new medicine called JSKN016HC for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and how it works in the body.
This trial tests a new cell therapy called ACE2016 for people with advanced solid tumors that have EGFR on their surface. It may be an option if you have tried at least two other treatments (including a targeted therapy) and your cancer is still growing.
Hear when a new Solid Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.